Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30006592 | 1.00 | CYP3A4 (0.42) | CYP3A4ATMHTR3EHTR3BHTR3A | |
| SCHEMBL28903834 | 0.89 | ACACB (0.44) | ATMALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL5046540 | 0.83 | ACACB (0.48) | GPR183 | |
| SCHEMBL4656696 | 0.81 | CYP3A4 (0.45) | CYP3A4ATMHTR3EHTR3BHTR3A | |
| SCHEMBL24419876 | 0.79 | BCL2L1 (0.38) | CYP3A4ALDH1A1HSD17B10TDP1KDM4E | |
| SCHEMBL23252170 | 0.76 | CYP3A4 (0.46) | CYP3A4ATMALDH1A1HSD17B10TDP1 | |
| SCHEMBL5046911 | 0.75 | ACACB (0.53) | CYP3A4ATMALDH1A1HSD17B10TDP1 | |
| SCHEMBL16329717 | 0.74 | MEN1 (0.47) | CYP3A4ALDH1A1SMN1; SMN2NPC1MAPT | |
| SCHEMBL3671715 | 0.74 | ATM (0.50) | ATMALDH1A1KDM4ESMN1; SMN2NPC1 | |
| SCHEMBL2156716 | 0.73 | ALDH1A1 (0.50) | CYP3A4ATMALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-01 | — | — | US | disclosed |
| CN-111808023-B | Method for preparing 3-aryl isoquinoline derivative | 四川大学 | 2022-10-21 | — | — | CN | disclosed |
| US-20210317107-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-10-14 | — | — | US | disclosed |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-20 | — | — | US | disclosed |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-20 | — | — | US | disclosed |
| CN-112566636-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-3784234-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919885-B2 | Compounds and uses thereof | YUMANITY THERAPEUTICS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| CN-111808023-A | Novel method for preparing 3-arylisoquinoline derivative | 四川大学 | 2020-10-23 | — | — | CN | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-31 | — | — | US | disclosed |
| WO-2018160967-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919885-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | CYP3A4 1178/4885ATM 4365/4885HTR3E 661/4885 |
| US-20210317107-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | MELK, HIPK1, HIPK3 | CYP3A4 4805/4885ATM 662/4885HTR3E 505/4885 |
| US-20190330198-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | CYP3A4 1178/4885ATM 4365/4885HTR3E 661/4885 |
| US-10981896-B2 | Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase | MELK, HIPK1, HIPK3 | CYP3A4 4783/4885ATM 694/4885HTR3E 611/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | CYP3A4 632/4885ATM 2013/4885HTR3E 4519/4885 |
| US-20250136580-A1 | INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE | MELK, HIPK1, HIPK3 | CYP3A4 4805/4885ATM 662/4885HTR3E 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.